Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUMSCs in Acute Basal Ganglia Hematoma
NCT04074408Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2020
- Primary completion
- Nov 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of human umbilical cord mesenchymal stem cells in basal ganglia hemorrhage (2 cohorts), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Frequency of dose limiting adverse events at 3 days, Modified Rankin Scale at 3 months and 3 more. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
basal ganglia hemorrhage
Beyond the preview
Go deeper on NCT04074408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04074408.